Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report

Area of Science:

• Infectious Diseases
• Hematology
• Critical Care Medicine

Background:

• The 2019 novel coronavirus (SARS-CoV-2) pandemic led to widespread critical illness.
• Severe SARS-CoV-2 cases frequently present with complex coagulation and hematologic abnormalities.
• Elevated D-dimer and fibrin/fibrinogen levels are associated with increased morbidity and mortality in COVID-19 patients.

Purpose of the Study:

• To present a case series evaluating an aggressive anticoagulation strategy.
• To highlight the benefits of anti-Xa level monitoring in managing COVID-19-associated coagulopathy.

Main Methods:

• Implementation of aggressive anticoagulation therapy.
• Monitoring of peak anti-Xa levels to guide treatment intensity.
• Retrospective analysis of patient outcomes at the institution.

Main Results:

• Anticoagulation therapy demonstrated satisfactory results in managing hematologic abnormalities.
• Effective management of elevated D-dimer and fibrin/fibrinogen levels was observed.
• The strategy contributed to improved patient outcomes in severe COVID-19 cases.

Conclusions:

• Aggressive anticoagulation with anti-Xa level monitoring is a beneficial approach for severe COVID-19 patients.
• This strategy effectively addresses SARS-CoV-2-related coagulation and hematologic issues.
• The findings support the use of this therapeutic approach in managing COVID-19 coagulopathy.